Analysis of rational usage of meropenem in our hospital

doi:10.12092/j.issn.1009-2501.2018.08.017

Abstract

Abstract:

AIM: To analyze the situation of clinical usage of meropenem in our hospital and to promote the rational usage of meropenem. METHODS: Ninety-seven medical records of meropenem hospitalized in our hospital from January 2016 to December 2017 were retrospectively analyzed for the drug usage, clinical efficacy, adverse reactions, and rationality of medication. RESULTS:Of the 97 patients, the top 3 departments using meropenem were surgical intensive care unit (23 cases, 23.71%), internal medicine intensive care unit (14 cases, 14.43%), and respiratory medicine department (11 cases, 11.34%). Seventy-six cases were cultured with bacteria, the submission rate was 78.35%, the defined daily doses (DDDs) of meropenem were 756.8, the drug utilization index (DUI) was 1.16, the adverse reaction rate was 15.46%, the total effective rate of clinical treatment was 85.57%, and the rational drug usage rate was 87.63%. The irrational drug usage rate was 12.37%, of which the non-indicative drug usage accounted for the highest proportion in all unreasonable drug usage cases. CONCLUSION: The clinical application of meropenem in our hospital is basically reasonable, but there are also cases of irrational usage. Clinical prescribes of meropenem should strictly follow the regulations to reduce experience-directed drug usage, improve the submission rate in order to enhance the efficacy of rational drug usage.

Key words: meropenem, rational drug usage, clinical efficacy, adverse reactions

CLC Number:

R978

WANG Mengzhi, WEI Yuguang, HUANG Xiaoling. Analysis of rational usage of meropenem in our hospital[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(8): 937-941.

References

［1］Fan B, Guan J, Wang X, et al. Activity of colistin in combination with meropenem, tigecycline, fosfomycin, fusidic acid, rifampin or sulbactam against extensively drug-resistantacinetobacter baumanniiin a murine thigh-infection model［J］. Plos One, 2016, 11(6): e0157757.
［2］姜飞, 邓丽华, 李洪春, 等. 鲍曼不动杆菌美罗培南体外诱导后对常用抗菌药物敏感性降低及其机制研究［J］. 中华临床感染病杂志, 2016, 9(3): 230-235.
［3］蒋伟, 王思淼, 金鑫. 耐碳青霉烯类抗菌药物的肠杆菌科细菌耐药性与分子特征分析［J］. 中华医院感染学杂志, 2017, 27(8): 1696-1698.
［4］Tiberi S, Sotgiu G, D'Ambrosio L, et al. Comparison of effectiveness and safety of imipenem/clavulanate-versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB［J］. Eur Resp J, 2016, 47(6): 1758-1766.
［5］Mazuski JE, Gasink LB, Armstrong J, et al. Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program［J］. Clin Infect Dis Official Pub Infect Dis Soc Am, 2016, 62(11): 1380-1389.
［6］韦志英. 我院美罗培南使用情况和耐药现状分析［J］. 中国合理用药探索, 2017, 14(8): 75-77.
［7］梁艳粉. 呼吸内科碳青霉烯类抗生素的应用情况及用药合理性分析［J］. 河北医药, 2017, 39(21): 3336-3339.
［8］马荣伟, 王莉. 美罗培南治疗新生儿重症细菌感染的临床疗效及安全性分析［J］. 中国药物与临床, 2016, 16(10):1481-1482.
［9］刘温娟, 王秀玲, 鲁立文, 等. 延长美罗培南输注时间治疗肺部重症感染疗效和安全性的系统评价［J］. 解放军药学学报, 2016, 10(4): 360-363.
［10］顾红燕, 金锐, 谢猛, 等. 药学干预在医院美罗培南不合理使用管理中的作用［J］. 中国医院药学杂志, 2016, 36(14): 1209-1212.
［11］吴玉婷. 美罗培南致药物性肝损伤1例［J］. 中国药物应用与监测, 2017, 14(1): 66-68.
［12］余美玲. 多粘菌素B联合美罗培南用于泛耐药铜绿假单胞菌体外抗菌活性的有效性分析［J］. 中国医学创新, 2015, 12(4): 112-115.
［13］李灵红. 某院特殊使用级抗菌药物应用情况分析［J］. 山东医药, 2016, 56(2): 60-61.
［14］靳蓉, 朱曼. 从1例重症肺部感染患者探讨美罗培南的优化给药方案［J］. 中国药物应用与监测, 2014, 11(6): 355-358.
［15］Brownelliott BA, Killingley J, Vasireddy S, et al. In Vitro comparison of ertapenem, meropenem, and imipenem against isolates of rapidly growing mycobacteria and nocardia using broth microdilution and e-tests ［J］. J Clin Microbiol, 2016, 54(6): 1586.
［16］Wang YC, Kuo SC, Yang YS, et al. Individual or combined effects of meropenem, imipenem, sulbactam, colistin, and tigecycline on biofilm-embedded acinetobacter baumannii and biofilm architecture［J］. Antimicrobial Agents Chemotherapy, 2016, 60(8): 4670.
［17］袁计生, 房大明, 李俊芳. 美罗培南联合喜炎平治疗老年脑卒中并发院内获得性肺炎62例分析［J］. 疑难病杂志, 2010, 9(6): 441-442.
［18］刘晓琳, 肖延民, 贾焕霞, 等. 碳青霉烯类抗菌药物在临床应用中的用药频度、耐药性调查及用药合理性分析［J］. 中国合理用药探索, 2017, 14(5): 19-22.
［19］曾上飞, 郑海军, 杨晓清, 等. 神经外科患者术后颅内医院感染的调查与抗菌药物使用分析［J］. 中华医院感染学杂志, 2016, 26(9): 2015-2017.
［20］王东晓, 李莉, 朱曼. 从1例老年感染患者探讨碳青霉烯类药物与丙戊酸钠的药物相互作用［J］. 中国药物应用与监测, 2013, 10(2): 87-90.

[1]	XU Yiqi, WU Qian, LIU Shu, LIU Fan, XING Chunyan, LI Qin, HE Junjun, HE Chunling, ZHAO Yongli, GAO Jialin. Clinical efficacy and anti-inflammation/anti-fibrosis effect of tripterygium glycosides in the treatment of diabetic nephropathy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1034-1042.
[2]	LI Xinyu, HUANG Xin. State of clinical application of meloxicam [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 189-197.
[3]	YE Hongbo, SONG Yangyang, XUE Ling, RUI Jianzhong. Meropenem population pharmacokinetic model for the Chinese elderly established by model-based META analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 984-990.
[4]	YANG Mengjiao, YUAN Hao, ZHENG Ya, WANG Yuping, GUO Qinghong. Advances in the treatment of potassium-competitive acid blockers in reflux esophagitis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1190-1196.
[5]	HUANG Yiting, SHEN Aizong. Clinical research progress of afatinib therapy for lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 474-480.
[6]	XING Kai, GONG Jinyu, LUO Jianquan. Advances on pharmacogenomics of diuretics-related adverse reactions [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(2): 204-212.
[7]	LIN Rongfang, ZHENG Weiwei, LIU Yiwei, LIN Cuihong, WANG Changlian, HUANG Pinfang. Correlation of infliximab related genetic polymorphism, serum trough concentration and efficacy in patients with Crohn's disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1000-1006.
[8]	ZHANG Lu, LIN Liangmo, LIU Keke, HUANG Yamin, HUANG Xingxing, YANG Yongyu, XIAO Jian. Therapeutic drug monitoring and pharmacokinetics of new coronavirus pneumonia antiviral drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 566-575.
[9]	. Research progress of linezolid-induced lactic acidosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(12): 1408-1413.
[10]	SONG Xin, WANG Xue, ZHOU Huanghong, ZHAO Tianyi. Effect of compound glycyrrhizin on the expression and clinical prognosis of antibacterial peptide LL-37 in patients with pigmentary purpuric skin disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(4): 458-463.
[11]	ZHU Tingfu, ZOU Chaochun. Clinical effect of Bailing capsule in children with diabetic renal injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(8): 912-915.
[12]	ZENG Chuanli, HU Airong, HU Yaoren, YUAN Gang, ZHU Dedong, SHI Xiaojun. Clinical effect of entecavir combined with probiotics on treatment of patients with hepatitis B cirrhosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(7): 796-801.
[13]	CHEN Lanfang, QIANG Fuyong, XU Liang. Short-term clinical observation of moderate to severe active rheumatoid arthritis treated with tocilizumab combined with disease modifying antirheumatic drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(12): 1386-1391.
[14]	MO Yali, XIA Yong, LIU Yi, TAO Yunhai, JIN Man. Effects of huperzine A combined with escitalopram on clinical efficacy and cognitive function in depression patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(9): 1040-1044.
[15]	WU Yonglei, WANG Dan, ZHANG Suiyang, WANG Ying, SUN Qin. Pharmacokinetics and pharmacodynamics of meropene administered by traditional prolonged infusion or optimized prolonged infusion in different tissues of septic rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(7): 767-774.